ImmuPharma plc (AIM:IMM)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 17.49M |
| Revenue (ttm) | -69.96K |
| Net Income (ttm) | -2.46M |
| Shares Out | 416.44M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,628,081 |
| Average Volume | 13,034,008 |
| Open | 4.900 |
| Previous Close | 4.600 |
| Day's Range | 4.120 - 4.900 |
| 52-Week Range | 0.822 - 7.400 |
| Beta | 2.55 |
| RSI | 51.69 |
| Earnings Date | Feb 21, 2025 |
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of ... [Read more]
Financial Performance
Financial StatementsNews
AIM Market Roundup: Immupharma, Poolbeg, Xeros
ImmuPharma, Poolbeg Pharma, Xeros Technology, RBG Holdings, Coro Energy are today's biggest risers and fallers on London's AIM market
Three Quick Facts: Norman Broadbent, Computacenter, Immupharma
Norman Broadbent, Computacenter, ImmuPharma are Tony Cross's three picks from today's financial market news